Sab Biotherapeutics Stock Debt To Equity

SABS Stock

USD 3.07 0.01 0.33%

SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.03	0.03

Debt To Equity is likely to gain to 0.03 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SAB Biotherapeutics Company Debt To Equity Analysis

SAB Biotherapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current SAB Biotherapeutics Debt To Equity

0.16 %

Most of SAB Biotherapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

SAB Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Debt To Equity. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Deferred Long Term Liab	Treasury Stock
Total Assets		0.98	0.96	-0.87	-0.56	0.26	0.92	0.26	0.69	0.98	-0.86	0.99	-0.65	0.86	0.07	-0.38	0.98	0.64	0.7	-0.66	0.66
Total Stockholder Equity	0.98		0.97	-0.85	-0.57	0.3	0.9	0.32	0.54	1.0	-0.81	0.96	-0.64	0.86	0.17	-0.4	0.96	0.65	0.75	-0.71	0.68
Net Tangible Assets	0.96	0.97		-0.74	-0.41	0.48	0.86	0.47	0.55	0.97	-0.9	0.91	-0.48	0.77	-0.04	-0.22	0.98	0.5	0.61	-0.62	0.5
Net Debt	-0.87	-0.85	-0.74		0.86	0.2	-0.91	0.16	-0.64	-0.85	0.61	-0.89	0.94	-0.96	-0.39	0.72	-0.8	-0.91	-0.82	0.78	-0.88
Retained Earnings	-0.56	-0.57	-0.41	0.86		0.59	-0.74	0.54	-0.31	-0.58	0.18	-0.59	0.95	-0.78	-0.75	0.79	-0.47	-0.94	-0.9	0.88	-0.91
Accounts Payable	0.26	0.3	0.48	0.2	0.59		0.0	0.98	0.01	0.3	-0.56	0.2	0.49	-0.06	-0.66	0.5	0.36	-0.43	-0.29	0.25	-0.41
Long Term Debt	0.92	0.9	0.86	-0.91	-0.74	0.0		-0.02	0.65	0.9	-0.76	0.87	-0.75	0.83	0.22	-0.4	0.92	0.72	0.81	-0.85	0.68
Net Receivables	0.26	0.32	0.47	0.16	0.54	0.98	-0.02		-0.06	0.32	-0.51	0.22	0.42	0.01	-0.58	0.37	0.33	-0.34	-0.27	0.24	-0.33
Total Liab	0.69	0.54	0.55	-0.64	-0.31	0.01	0.65	-0.06		0.53	-0.72	0.69	-0.46	0.53	-0.29	-0.16	0.69	0.34	0.23	-0.21	0.31
Net Invested Capital	0.98	1.0	0.97	-0.85	-0.58	0.3	0.9	0.32	0.53		-0.8	0.96	-0.64	0.86	0.18	-0.4	0.96	0.66	0.76	-0.72	0.69
Short Long Term Debt	-0.86	-0.81	-0.9	0.61	0.18	-0.56	-0.76	-0.51	-0.72	-0.8		-0.79	0.31	-0.62	0.42	0.02	-0.92	-0.28	-0.3	0.38	-0.21
Total Current Assets	0.99	0.96	0.91	-0.89	-0.59	0.2	0.87	0.22	0.69	0.96	-0.79		-0.7	0.89	0.14	-0.48	0.94	0.69	0.7	-0.61	0.73
Capital Stock	-0.65	-0.64	-0.48	0.94	0.95	0.49	-0.75	0.42	-0.46	-0.64	0.31	-0.7		-0.9	-0.61	0.89	-0.55	-0.99	-0.81	0.76	-0.94
Net Working Capital	0.86	0.86	0.77	-0.96	-0.78	-0.06	0.83	0.01	0.53	0.86	-0.62	0.89	-0.9		0.35	-0.78	0.78	0.91	0.75	-0.71	0.86
Short Term Debt	0.07	0.17	-0.04	-0.39	-0.75	-0.66	0.22	-0.58	-0.29	0.18	0.42	0.14	-0.61	0.35		-0.66	-0.05	0.65	0.73	-0.61	0.74
Common Stock	-0.38	-0.4	-0.22	0.72	0.79	0.5	-0.4	0.37	-0.16	-0.4	0.02	-0.48	0.89	-0.78	-0.66		-0.23	-0.91	-0.59	0.5	-0.87
Property Plant Equipment	0.98	0.96	0.98	-0.8	-0.47	0.36	0.92	0.33	0.69	0.96	-0.92	0.94	-0.55	0.78	-0.05	-0.23		0.53	0.63	-0.64	0.53
Current Deferred Revenue	0.64	0.65	0.5	-0.91	-0.94	-0.43	0.72	-0.34	0.34	0.66	-0.28	0.69	-0.99	0.91	0.65	-0.91	0.53		0.83	-0.79	0.95
Capital Surpluse	0.7	0.75	0.61	-0.82	-0.9	-0.29	0.81	-0.27	0.23	0.76	-0.3	0.7	-0.81	0.75	0.73	-0.59	0.63	0.83		-0.95	0.88
Deferred Long Term Liab	-0.66	-0.71	-0.62	0.78	0.88	0.25	-0.85	0.24	-0.21	-0.72	0.38	-0.61	0.76	-0.71	-0.61	0.5	-0.64	-0.79	-0.95		-0.75
Treasury Stock	0.66	0.68	0.5	-0.88	-0.91	-0.41	0.68	-0.33	0.31	0.69	-0.21	0.73	-0.94	0.86	0.74	-0.87	0.53	0.95	0.88	-0.75

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict SAB Biotherapeutics

Debt To Equity Over Time

SAB Total Stockholder Equity

Total Stockholder Equity

35.99 Million

At this time, SAB Biotherapeutics' Total Stockholder Equity is comparatively stable compared to the past year.

According to the company disclosure, SAB Biotherapeutics has a Debt To Equity of 0.164%. This is 99.69% lower than that of the Biotechnology sector and 99.15% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.66% higher than that of the company.

SAB Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.

SAB Biotherapeutics is currently under evaluation in debt to equity category among its peers.

SAB Biotherapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SAB Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SAB Biotherapeutics' managers, analysts, and investors.

Environmental

Governance

Social

SAB Fundamentals

	Return On Equity	-1.75
	Return On Asset	-0.79
	Operating Margin	(34.23) %
	Current Valuation	2.45 M
	Shares Outstanding	9.23 M
	Shares Owned By Insiders	19.15 %
	Shares Owned By Institutions	34.24 %
	Number Of Shares Shorted	58.76 K
	Price To Book	0.77 X
	Price To Sales	18.73 X
	Revenue	2.24 M
	Gross Profit	(12.53 M)
	EBITDA	(38.13 M)
	Net Income	(42.19 M)
	Cash And Equivalents	16.62 M
	Cash Per Share	0.39 X
	Total Debt	5.91 M
	Debt To Equity	0.16 %
	Current Ratio	1.72 X
	Book Value Per Share	4.00 X
	Cash Flow From Operations	(25.12 M)
	Short Ratio	0.54 X
	Earnings Per Share	(6.30) X
	Target Price	12.4
	Number Of Employees	57
	Beta	0.64
	Market Capitalization	28.33 M
	Total Asset	83.94 M
	Retained Earnings	(90.06 M)
	Working Capital	48.09 M
	Net Asset	83.94 M

About SAB Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC